

AD _____

Award Number: DAMD17-00-1-0484

TITLE: C/EBP β Isoforms - An Innovative Transcription Factor
Therapy for Breast Cancer

PRINCIPAL INVESTIGATOR: Linda J. Sealy, Ph.D.

CONTRACTING ORGANIZATION: Vanderbilt University
Nashville, Tennessee 37232-2103

REPORT DATE: May 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20021001 095

| REPORT DOCUMENTATION PAGE | | | Form Approved OMB No. 074-0188 | |
|---|---|---|---|--|
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503 | | | | |
| 1. AGENCY USE ONLY (Leave blank) | 2. REPORT DATE May 2002 | 3. REPORT TYPE AND DATES COVERED Annual (1 May 01 - 30 Apr 02) | | |
| 4. TITLE AND SUBTITLE C/EBP β Isoforms - An Innovative Transcription Factor Therapy for Breast Cancer | | 5. FUNDING NUMBERS DAMD17-00-1-0484 | | |
| 6. AUTHOR(S) Linda J. Sealy, Ph.D. | | | | |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Vanderbilt University Nashville, Tennessee 37232-2103 E-Mail: linda.sealy@mcmail.vanderbilt.edu | | 8. PERFORMING ORGANIZATION REPORT NUMBER | | |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 | | 10. SPONSORING / MONITORING AGENCY REPORT NUMBER | | |
| 11. SUPPLEMENTARY NOTES Report contains color graphics | | | | |
| 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited | | | 12b. DISTRIBUTION CODE | |
| 13. ABSTRACT (Maximum 200 Words) The transcription factor, C/EBP β , is critical for growth and differentiation of the mammary gland. Three forms of C/EBP β are expressed in cells through alternative translation of the C/EBP β mRNA. C/EBP β -1 and -2 activate transcription; C/EBP β -2 is a truncated form that represses transcription. Based upon their distinct expression patterns in normal and transformed cells as well as functional studies, we propose that C/EBP β -1 and -3 (or both) will be potent anti-tumor therapies when used either singly or in combination by suppressing the expression of genes which drive the cell cycle (C/EBP β -3) and/or reactivating a differentiation program (C/EBP β -1). The purpose of this study is to develop non-replicating murine retroviral and adenoviral vectors carrying genes selectively encoding either C/EBP β -1 or -3. These vectors will be used to efficiently re-express C/EBP β -1 and/or overexpress C/EBP β -3 in breast cancer cells lines and evaluate the growth potential of the cells. We have successfully generated murine retroviral vectors encoding C/EBP β -1 and C/EBP β -3 as well as an adenovirus encoding C/EBP β -3. We have infected breast cancer cell lines with each of these viruses and documented nuclear expression of C/EBP β -1 and -3 by both immunohistochemistry and immunoblotting. Studies on the growth potential of the infected cells are confidential and will be presented in the annual report. | | | | |
| 14. Subject Terms (keywords previously assigned to proposal abstract or terms which apply to this award) transcription factor, viral vector, anti-tumor therapy, C/EBP β | | | 15. NUMBER OF PAGES 27 | |
| | | | 16. PRICE CODE | |
| 17. SECURITY CLASSIFICATION OF REPORT Unclassified | 18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified | 19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified | 20. LIMITATION OF ABSTRACT Unlimited | |

Table of Contents

| | |
|-----------------------------------|-----|
| Cover..... | 1 |
| SF 298..... | 2 |
| Table of Contents..... | 3 |
| Introduction..... | 4 |
| Body..... | 4-6 |
| Key Research Accomplishments..... | 6 |
| Reportable Outcomes..... | 6 |
| Conclusions..... | 7 |
| References..... | 7 |
| Appendices..... | 8 |

INTRODUCTION

Gene deletion studies have shown that the transcription factor, C/EBPbeta, is critical for growth and differentiation of the mammary gland. Both increased epithelial cell proliferation in early pregnancy and differentiation at late pregnancy stages are strongly impaired in the absence of C/EBPbeta. Furthermore, C/EBPbeta null mice fail to lactate. Three forms of C/EBPbeta can be expressed in cells through alternative translation of the C/EBPbeta mRNA at one of three in frame methionines. C/EBPbeta-1 and C/EBPbeta-2 activate transcription; C/EBPbeta-3 is a truncated form that represses transcription. Because they are close in size, functional differences between C/EBPbeta-1 and -2 have never been investigated. Using an antibody we developed that is specific for C/EBPbeta-1, we made the novel discovery that C/EBPbeta-1 is expressed only in normal human mammary epithelial cells (HMECs) and ductal secretory epithelial cells from human breast milk, but not in any breast cancer cell lines we have examined (1). Moreover, C/EBPbeta-2 is sequestered in the cytoplasm in normal HMECs, but constitutively activated in the nucleus in breast cancer cells (1). Finally, C/EBPbeta-3 is expressed at high levels in growing HMECs, whereas some breast cancer cell lines lack this repressor (1). Based upon their expression pattern and other functional studies, we propose that C/EBPbeta-3 or 1 (or both) will be potent anti-tumor therapies when used either singly or in combination to inhibit tumor cell growth by suppressing the expression of genes which drive the cell cycle (C/EBPbeta-3) and/or reactivating a differentiation program (C/EBPbeta-1). To test this hypothesis we are developing non-replicating murine retroviral vectors and/or adenoviruses that carry genes selectively encoding either epitope-tagged C/EBPbeta-1 or C/EBPbeta-3. After infection with these viruses, we will evaluate the growth potential of breast cancer cells lines overexpressing either epitope-tagged C/EBPbeta-3 or epitope-tagged C/EBPbeta-1, or both.

BODY

TASK 1-3: Completed in year 01. See report covering May 1, 2000 to April 30, 2001.

TASK 4: To infect a representative panel of breast cancer cell lines with hisC/EBPbeta-3, hisC/EBPbeta-1 or control beta-gal retroviruses and analyze growth potential of the infected cells (months 6-24; status – ongoing).

Progress on task 4 will be divided into two sections, addressing either hisC/EBPbeta-1 or -3, respectively.

C/EBPbeta-1

In year 1, we demonstrated that primary normal human mammary epithelial cells (HMECs) obtained from reduction mammoplasty, as well as MCF-10As, and the breast cancer cell line, MDA 231, can be infected with hisC/EBPbeta-1-IRES-GFP retrovirus. hisC/EBPbeta-1 expression in the cells as monitored by immunofluorescent staining with T7tag antibody was seen to be primarily nuclear, as expected. We also prepared whole cell extracts from both hisC/EBPbeta-1-IRES-GFP and IRES-GFP infected cells as well as uninfected cells for analysis of protein expression levels by immunoblotting. (Note: Because we have included GFP as a marker protein in all of our retroviral constructs, we routinely use a chimeric retrovirus expressing just GFP as a control, rather than beta-gal.). Retroviral infection results in a high level of hisC/EBPbeta-1 expression in the cells, relative to the endogenous level of C/EBPbeta2. MDA-231 cells infected with hisC/EBPbeta-1-IRES-GFP retrovirus or IRES-GFP retrovirus were sorted by FACS. No differences were observed in the proportion of cells in S phase and the doubling time was not affected by C/EBPbeta-1 reexpression in these cells. However, we obtained an interesting result from the colony assay, in which C/EBPbeta-1 infected or control cells were plated at approximately 800 cells per 60mm dish. MDA 231s infected with C/EBPbeta-1 formed colonies of fewer cells than MDA 231s infected with GFP only. It is possible that introduction of C/EBPbeta-1 into these cells causes contact inhibition and

decreases their ability to grow on top of one another. To address this possibility, in year 02 we examined the ability of the cells to grow in matrigel, a synthetic basement membrane prepared from Englebreth-Holm-Swarm (EHS) tumor. MDA 231 cells form a characteristic highly branched, spindle growth pattern when placed in the matrigel environment; in contrast, cells which maintain their epithelial characteristics and are contact-inhibited form acinar structures (2).

As shown in Figure 1, MDA-231 cells reexpressing C/EBPbeta-1 no longer display the branching, stellate morphology of the control MDA 231 cells expressing GFP only. Instead, they grow with a fused, spherical morphology. These differences resemble those seen between invasive and non-invasive breast cancer cell lines (2). The fused, spherical morphology is typical of non-invasive cell lines such as MCF-7, whereas highly invasive, metastatic cell lines (MDA 231, MDA 435) exhibit a branching morphology as mentioned above. To confirm these studies we infected another highly invasive cell line, MDA 435, with hisC/EBPbeta-1-IRES-GFP retrovirus or IRES-GFP retrovirus. The invasive, branching growth of the untreated MDA 435 cells, or GFP only expressing cells, was completely blocked by C/EBPbeta-1 expression. As an additional control, expression of the C/EBPbeta-2 isoform, which is the transactivator isoform found in breast cancer cell lines and acquired by invasive human mammary carcinomas (1), had no effect on the growth pattern of MDA 435 cells in matrigel. These studies suggest that although the transformed MDA 231 and 435 cells do not form normal acinar structures, C/EBPbeta-1 expression may have a significant effect on reducing cell motility and invasive capacity.

Because of the morphologic changes we observed in the C/EBPbeta-1 expressing breast cancer cell lines, we decided to investigate the effect of this protein on behavior in an in vitro invasion assay. In this assay, cells must degrade a uniform barrier of matrigel and traverse a porous filter in response to a chemotactic gradient in a modified Boyden chamber. As seen in Figure 3, the C/EBPbeta-1 expressing MDA-231 and MDA-435 cells displayed a substantial reduction in invasion approaching 80%. Invasive activity was normalized to that of uninfected breast cancer cells included in each assay. This reduction was not observed in the control GFP-expressing cells. **We conclude that C/EBPbeta-1 expression is a potent inhibitor of invasive growth by mammary epithelial cells in culture.**

We are in the process of extending these studies using the nude mouse xenograft model as outlined in the Statement of Work. HisC/EBPbeta-1-IRES-GFP infected MDA 231 cells were first sorted by FACS to remove any uninfected or low expressing cells (see C/EBPbeta-3 below) and then implanted into the mammary pad of 10 female nude mice. We also implanted control GFP-infected and sorted cells into a separate group of 10 nude mice. However, instead of monitoring tumor latency and size as endpoints, we are comparing metastatic potential of the implanted cells. MDA 231 cells from the primary tumor typically metastasize to lungs of nude mice in 10-12 weeks (or by the time the primary tumor has reached approximately 1 cm) with nearly 100% frequency. We expect that C/EBPbeta-1 expressing MDA 231 cells will not metastasize or do so with lower frequency or reduced number of lung colonies. The experiment is ongoing and so far only one C/EBPbeta-1-MDA 231 xenograft mouse has developed a primary tumor 1cm in size (all other animals are currently in the 5-7 mm range). Upon sacrifice, no lung metastases were found from the C/EBPbeta-1-MDA 231 tumor, which is extremely exciting. As the next year of this grant begins, we will complete this study and extend the xenograft studies to MDA 435 cells.

C/EBPbeta-3

In year 01, we infected the breast cancer cell line, MDA 231, with hisC/EBPbeta-3-IRES-GFP retrovirus. hisC/EBPbeta-3 expression in the cells was monitored by immunofluorescent staining with T7tag antibody and shown to be entirely nuclear, as expected. Immunoblotting also confirmed substantial overexpression of C/EBPbeta-3 in the infected cells, clearly equaling or exceeding the amount of C/EBPbeta-2 endogenously present in the cells. We demonstrated that

MDA 231 cells overexpressing C/EBPbeta-3 are growth inhibited and drop from 50% to 8% of the population over a 2 week interval. In contrast, the number of GFP positive cells in the control IRES-GFP infected population is stable over the 4 week time course of the experiment, indicating that GFP alone does not impair the growth of the cells. Cell cycle profiles on the GFP positive cells overexpressing C/EBPbeta-3 suggested that this isoform of C/EBPbeta may cause growth arrest through a G2/M block.

Given these encouraging results, in year 02 we determined whether growth inhibition in culture extended to tumor formation in vivo in nude mice as outlined in the Statement of Work for the period 12-24 months. Xenograft studies, in which C/EBPbeta-3 expressing MDA 231 cells were implanted into the mammary pad of 10 female nude mice, showed no reduction in tumor size compared with control uninfected, or GFP expressing cells implanted in populations of 10 nude mice each. However, the latency of tumor formation was delayed. We attribute this outcome to the presence of cells in the population expressing a low level of C/EBPbeta-3 which is not sufficient to inhibit growth. To avoid this problem, we plan to sort hisC/EBPbeta-3-IRES-GFP infected MDA 231 cells by FACS, setting the gate to select only GFP positive cells of high fluorescent intensity. Since hisC/EBPbeta-3 and GFP are translated from the same bicistronic mRNA, those cells expressing high levels of GFP are also expressing high levels of hisC/EBPbeta-3. Therefore, we expect to remove the cells expressing only a low level of hisC/EBPbeta-3 prior to implantation. If this approach is successful, we will extend the studies to include other breast cancer cell lines.

KEY RESEARCH ACCOMPLISHMENTS (Year 02)

1. Reexpression of C/EBPbeta-1 blocks the invasive growth of human breast cancer cells in culture.

REPORTABLE OUTCOMES

Manuscripts:

Eaton, E., Hanlon, M., Bundy, L., and Sealy, L. (2001) Characterization of C/EBPbeta Isoforms in Normal vs. Neoplastic Mammary Epithelial Cells. *J. Cell. Physiology* **189**, 91-105.

Eaton, E. and Sealy, L. (2002) Reexpression of C/EBPbeta-1 in breast cancer cells blocks invasive growth. *Oncogene*, in preparation.

Abstracts:

Bundy, L.M., Eaton, E., Hanlon, M., and Sealy, L. (2001) Regulation of Mammary Epithelial Cell Growth by CCAAT/Enhancer Binding Protein Beta. *Mammary Gland Gordon Conference*, June 3-8, 2001.

CONCLUSIONS

In this first year of this grant we successfully developed several powerful tools to directly test whether C/EBPbeta-1 and -3 isoforms, which are missing or expressed at a low level in breast tumor cells, could be an effective anti-tumor therapy. We have in hand high titer, non-replicating retroviruses that encode either C/EBPbeta-1 or -3 and a high titer, non-replicating adenovirus that encodes C/EBPbeta-3. These viruses are capable of efficiently infecting human cells, so that after a single infection between 70 and 90% of the cells express the C/EBPbeta isoform of interest. The addition of an IRES and GFP to the retroviral constructs was a valuable modification, in that not only are the infected cells quickly identified, but they can also be sorted via FACS to provide a uniform population for study, without the need for lengthy drug selection. This is essential for the analysis of growth inhibitory proteins.

In the second year of the grant period, we analyzed the growth potential of breast cancer cell lines infected with C/EBPbeta-1 or -3 viruses. We found that although C/EBPbeta-1 may have some effects on restoring contact inhibition, clearly the most dramatic result is the complete inhibition of invasive growth in culture. Xenograft studies, currently ongoing, also appear promising in reducing or blocking metastatic growth of tumor cells by C/EBPbeta-1. Our initial xenograft studies of C/EBPbeta-3 infected breast cancer cells were not successful. However, we are able to address the problem of low expressing cells in the population, and will repeat these studies. We remain optimistic that combined expression of both C/EBPbeta-1 and -3 (task 5, year 3) will prove to be the most potent anti-tumor therapy in xenograft animal models, since both primary tumor growth (via beta-3) and metastatic potential (via beta-1) will be targeted.

REFERENCES

1. Eaton, E., Hanlon, M., Bundy, L., and Sealy, L. (2001) Characterization of C/EBPbeta Isoforms in Normal vs. Neoplastic Mammary Epithelial Cells. *J. Cell Physiology* 189, 91-1052.
2. Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu HL, Munishkin A, Beauheim C, Harvey S, Ethier SP, and Johnson PH. (2001) Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. *Cancer Res* 61, 5168-78.

APPENDIX

Contents:

Figures 1-3

Abstract: Bundy, L.M., Eaton, E., Hanlon, M., and Sealy, L. (2001) Regulation of Mammary Epithelial Cell Growth by CCAAT/Enhancer Binding Protein Beta. *Mammary Gland Gordon Conference*, June 3-8.


Reprint: Eaton, E., Hanlon, M., Bundy, L., and Sealy, L. (2001) Characterization of C/EBPbeta Isoforms in Normal vs. Neoplastic Mammary Epithelial Cells. *J. Cell Physiology* 189, 91-105.

Light Microscope


Fluorescent Microscope




A.



0.03 second exposure




B.




0.73 second exposure

10X magnification


Figure 1: MDA 231 cells infected with C/EBP β -1 and GFP (A) or GFP only (B) display different growth morphologies in 3 dimensional matrigel. Whereas MDA 231 cells infected with GFP only display a branching phenotype similar to parental cells (data not shown), cells infected with C/EBP β -1 and GFP fail to branch in the basement membrane. Confirmation that the cells forming the different patterns were expressing GFP, and consequently, C/EBP β -1, was obtained by visualizing the green fluorescence under a fluorescent microscope.




A. C/EBP β -1



B. C/EBP β -2



C. GFP only



D. No virus

Figure 2: Ability to alter growth morphology in matrigel is specific to the first isoform of C/EBP β . MDA 435s cells infected with C/EBP β -1 (**A**) fail to branch like cells infected with C/EBP β -2 (**B**), GFP only (**C**), or uninfected (**D**).




Figure 3: C/EBPβ-1 inhibits the in vitro invasive character of either MDA 231 or MDA 435s breast cancer cells. Uninfected cells, cells expressing only GFP, or cells expressing C/EBPβ-1 and GFP were collected, counted, and 1×10^4 cells were placed into growth factor deficient medium (0.5% FBS) in the tops of invasion chambers. The invasion chambers are modified Boyden chambers lined with a filter containing 8 micron pores and coated with a layer of matrigel that are placed into 24 well tissue culture plates containing NIH3T3 conditioned medium. In order for the cells to move from the growth factor deficient medium in the top to the growth factor enriched medium in the bottom, the cells must degrade the matrigel layer and migrate through the filter. After 18 hours, the top matrigel layer and any remaining cells were removed with a cotton swab. Cells on the underside of the filter were stained with Diff-Quik stain set from Dade-Behring and counted. Invasion is expressed as percentage of control (uninfected) cells. Data shown are results from three independent experiments, performed in duplicate.

**Regulation of Mammary Epithelial Cell Growth by
CCAAT/Enhancer Binding Protein β (C/EBP β)**

Linda M. Bundy, Erin Eaton, Mary Hanlon, and Linda Sealy, Department of Molecular Physiology & Biophysics, Vanderbilt University Medical School, Nashville, TN 37232

ABSTRACT

Gene knockout studies show that the transcription factor, C/EBP β , is critical for growth and differentiation of the mammary gland during puberty, pregnancy, lactation, and involution. Three forms of C/EBP β can be expressed in cells. C/EBP β -1 and C/EBP β -2 activate transcription; C/EBP β -3 is a truncated form that represses transcription. C/EBP β -1 is found exclusively in normal mammary epithelial cells, whereas C/EBP β -2 is found only in dividing cells, both normal and neoplastic. Our preliminary data suggest that the prevalent form of C/EBP β in cancer cells, C/EBP β -2, is associated with an invasive phenotype. To examine the distinct functions of these isoforms, we have generated recombinant amphotropic retrovirus carrying genes selectively encoding epitope-tagged C/EBP β of each isoform using a hybrid Epstein-Barr virus (EBV)/retroviral vector construct (LZRSpBMN-Z) developed and provided to us by G. Nolan (Stanford University).

Although C/EBP β -1 and -2 are both transactivators, our laboratory has shown that they are differentially expressed. Using an antibody we developed that is specific for C/EBP β -1, we made the novel discovery that C/EBP β -1 is expressed in normal human mammary epithelial cells (HMECs) and ductal secretory epithelial cells harvested from human breast milk, but absent in all breast cancer cell lines examined. Moreover, MCF10As, an immortal but "normal" human mammary epithelial cell line, engineered to overexpress C/EBP β -2 acquire transformed characteristics: they form foci, gain anchorage independence, become invasive, and express mesenchymal markers. Based upon these observations, and other data, we propose that C/EBP β -1 promotes differentiation while C/EBP β -2 promotes proliferation in mammary epithelial cells. We hypothesize that mammary tumors exhibit deregulated growth because of constitutive activation of C/EBP β -2 in the nucleus, coupled in many cases with a lack of C/EBP β -3. Lastly, we will present data demonstrating that overexpression of the dominant negative C/EBP β -3 isoform acts as a potent inhibitor of growth in human breast cancer cell lines.

Characterization of C/EBP β Isoforms in Normal Versus Neoplastic Mammary Epithelial Cells

ERIN M. EATON, MARY HANLON, LINDA BUNDY, AND LINDA SEALY*

*Department of Molecular Physiology and Biophysics,
Vanderbilt University School of Medicine, Nashville, Tennessee*

A member of the CCAAT Enhancer Binding Proteins (C/EBPs) family of transcription factors, C/EBP β , has recently proven to be an important player in both growth and differentiation of the epithelial cells in the mammary gland. When the gene for C/EBP β is disrupted in mice, these mice fail to either develop normal mammary ducts during puberty or pregnancy, or to lactate upon parturition. C/EBP β can be present in cells in three isoforms: C/EBP β -1, -2, and -3. These isoforms have the same carboxy terminus but different N-termini due to alternative translational initiation at three different initiator codons within the C/EBP β mRNA. Using a commercially available antibody specific to the C-terminus of C/EBP β and a novel antibody specific to the N-terminus of C/EBP β -1, we have uncovered a striking difference in the forms of C/EBP β present in normal mammary epithelial cells versus breast cancer cell lines. C/EBP β -1 is found exclusively in normal mammary epithelial cells, whereas C/EBP β -2 is found only in dividing cells, both normal and neoplastic. Our preliminary data suggest that the prevalent form of C/EBP β in cancer cells, C/EBP β -2, can activate genes which push the cell to divide, such as cyclin D1. *J. Cell. Physiol.* 189: 91–105, 2001. © 2001 Wiley-Liss, Inc.

The CCAAT Enhancer Binding Proteins (C/EBPs) are a family of basic leucine zipper transcription factors. These proteins play a variety of roles in multiple different cell types (reviewed in Lékstrom-Himes and Xanthopoulos, 1998). One member of this family, C/EBP β , has recently proven to be essential in mammary epithelial cells. Transgenic mice, which lack the C/EBP β gene, fail to develop normal mammary glands at puberty or pregnancy, or to lactate upon parturition (Robinson et al., 1998; Seagroves et al., 1998). These mice, therefore, display a dual phenotype: a defect in mammary epithelial cell proliferation in response to hormonal stimulation at puberty or pregnancy and a defect in mammary epithelial cell differentiation in response to lactation specific hormones. Failure of these mice to lactate is perhaps not too surprising, since C/EBP β has been implicated in the regulation of milk-specific genes such as beta-casein (Doppler et al., 1995; Raught et al., 1995). Failure of the epithelial cells to proliferate at puberty or pregnancy is more unexpected, as C/EBP β is commonly thought regulate differentiation specific genes rather than proliferation specific genes.

Alternative translation of the intronless C/EBP β gene produces three different protein isoforms possibly due to leaky ribosome scanning (Descobes and Schibler, 1991). However, an alternative mechanism recently has been proposed involving regulation by the mRNA binding protein CUGBP1 (Timchenko et al., 1999). C/EBP β -1 and -2, initiated at the first and second in-frame methionines respectively, activate transcrip-

tion. Either translation initiation at the third in-frame methionine, or, as recent studies suggest, proteolytic cleavage of C/EBP β (Baer and Johnson, 2000), generates a small 20 kD protein, C/EBP β -3, which lacks the N-terminal transactivation domain and therefore represses transcription (see Fig. 1). Only recently have groups begun to study the functional differences between the two activator proteins (Kowenz-Leutz and Leutz, 1999). Because human C/EBP β -1 and C/EBP β -2 differ by only 23 amino acids (the mouse, rat, and chicken proteins differ by only 21 amino acids), it is difficult to distinguish between phosphorylated C/EBP β -2 and C/EBP β -1 using the commercially available antibody, which recognizes an epitope at the C-terminus of the protein. To unequivocally distinguish the activator isoforms, we developed an antibody specific to the N-terminal amino acids present in human C/EBP β -1 but absent in C/EBP β -2. Using this antibody, we have observed a striking difference in the expression of

Contract grant sponsor: NIH; Contract grant numbers: 2T32DK07563-13, 2T32GM08554-06; Contract grant sponsor: Susan G. Komen Breast Cancer Research Foundation.

*Correspondence to: Linda Sealy, Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232.

E-mail: linda.sealy@mcmail.vanderbilt.edu

Received 22 June 2001; Accepted 22 June 2001

Published online in Wiley InterScience, 16 August 2001.

these two activator isoforms between human breast cancers and normal human breast cells from both established human cell lines and primary tissues. C/EBP β -1 is present in all normal cells and tissues examined but absent in all the breast cancer cell lines examined. C/EBP β -2 is found only in actively or potentially dividing cells but not in mainly quiescent differentiated tissues.

To determine whether the distinct expression profiles could also have functional significance, we examined a gene known to be important in breast development and carcinogenesis, cyclin D1. Cyclin D1 regulates the G1-S phase of the cell cycle. It and its catalytic partners, the cyclin dependent kinases (CDKs) 4 and 6, phosphorylate pRb. This phosphorylation inactivates pRb, which leads to the release of the transcription factor E2F, a protein necessary to activate genes involved in DNA replication (reviewed in Sherr, 1996). Deletion of the cyclin D1 gene in transgenic mice creates a phenotype in the mammary gland very similar to that seen in the C/EBP β knockout mice (Fantl et al., 1995; Sicinski et al., 1995) in that mammary glands of these mice fail to proliferate upon hormonal stimulation at puberty or pregnancy. Cyclin D1 is implicated in breast cancer as well. Transgenic mice overexpressing cyclin D1 in the mammary gland via the MMTV promoter develop mammary hyperplasia and carcinoma (Wang et al., 1994). The cyclin D1 gene is amplified in 15–20% of breast cancers; the protein or mRNA is overexpressed in approximately 50% of breast cancers (Buckley et al., 1993; Bartkova et al., 1994).

In transient transfections, C/EBP β -2 activates the cyclin D1 promoter while C/EBP β -1 does not. In fact, it slightly represses this promoter. Taken together with their different expression profiles, we propose that the two C/EBP β activator proteins have functionally distinct roles within mammary epithelial cells with C/EBP β -2 promoting growth and C/EBP β -1 regulating the transcription of genes in non-proliferating or differentiating cells.

MATERIALS AND METHODS

Western analyses

Whole cell extracts were prepared from subconfluent cultures of breast cancer cell lines and 81N cells (kind

gifts of Dr. Carlos Arteaga, Vanderbilt University) or normal mammary epithelial cells in culture (HMECs from Clonetics, Walkersville, MD) or immortalized MCF10A cells (ATCC, Rockville, MD) by scraping the cells at 4°C into STE (10 mM Tris pH 8, 1 mM EDTA, 100 mM NaCl) plus protease/phosphatase inhibitors (10 μ M Na vanadate, 10 mM Na molybdate, 10 mM beta-glycerolphosphate, 1 μ g/ml aprotinin, 1 μ g/ml leupeptin, 1 μ g/ml pepstatin, and 1 mM phenylmethylsulfonyl fluoride), adding an equal volume of 2 \times Laemmli sample buffer (Biorad, Melville, NY) and boiling for 10 min. Mammary ductal epithelial cells (MDEs) were collected from freshly collected breast milk of one of the authors of this paper. Milk samples were centrifuged at 1,000g for 5 min. Supernatant was aspirated then cells were washed in phosphate buffered saline (PBS) plus 0.1 mM Na Vanadate at 4°C and recollected at 1,000g for 5 min. The cell pellets were resuspended in STE plus protease/phosphatase inhibitors and an equivalent volume of 2 \times Laemmli sample buffer as above. Crude nuclear and cytoplasmic extracts were prepared from the cell lines by gentle lysis at 4°C in Buffer A (10 mM HEPES, pH 8, 0.5 M sucrose, 50 mM NaCl, 1 mM EDTA, 0.25 mM EGTA, 0.5 mM spermidine, 0.15 mM spermine, 0.5% Triton X-100, and 7 mM β -mercaptoethanol) plus the protease/phosphatase inhibitors given above, followed by centrifugation at 600g. The supernatant (cytoplasm) was removed and combined with an equivalent amount of 2 \times Laemmli sample buffer and the pellet (nuclei) was resuspended in 1 \times Laemmli sample buffer. Relative protein concentrations were determined using Biorad Protein Assay Reagent, as described by the manufacturer, and equivalent amounts of sample were analyzed by sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE). Immunoblotting was performed as previously described (Hanlon and Sealy, 1999) using C/EBP β antibody specific to the C terminus of C/EBP β (Santa Cruz Biotechnologies, Inc., Santa Cruz, CA) or N terminal C/EBP β antibody.

N-terminal antibody synthesis

A rabbit polyclonal antibody was raised to a KLH-conjugated 16 amino acid peptide (MQRLVAWD-PACLPLPP) corresponding to amino acids 1–16 of human C/EBP β (also called NF-IL6). This 16 aa peptide




Fig. 1. Schematic representation of the C/EBP β protein isoforms, showing ATG start sites of the three protein isoforms as well as binding sites for the antibodies used in the following experiments. Numbering is for the human C/EBP β gene, NFIL6. The rat gene, called LAP, is 297 amino acids, and the difference between rat C/EBP β -1

and -2 (also called LAP* and LAP) is only 21 amino acids. Because of 4 amino acid differences in the N-terminal epitope between NFIL6 and LAP, the antibody recognizes human C/EBP β -1 but LAP* poorly if at all.

is only 75% conserved in the rat and mouse C/EBP β proteins (also called LAP) and we have found experimentally that the antibody raised to the above peptide is fairly human-specific, recognizing rat/mouse C/EBP β -1 very poorly if at all. The antibody was generated at East Acres Biologicals (Southbridge, MA) following their protocols. To obtain affinity-purified antibody, antiserum from production bleeds was incubated with purified, bacterially-expressed NF-IL6 protein that had been immobilized on Immobilon-P filter strips overnight at 4°C. The antigen-antibody containing strips were washed at room temperature 4 times in Tris-buffered saline plus 0.05% Tween 20 (TBS-T), once with TBS-T containing 1M NaCl, and then a final wash with TBS-T. Antibody was eluted from the antigen-containing strips by incubation in 0.2 M glycine, pH 2.2 containing 0.2% phenol red. Eluted antibody was immediately neutralized by the addition of sufficient 1.5 M Tris pH 9 to bring the pH to 7.0 and BSA was added to a final concentration of 1 mg/ml.

Immunoprecipitations

HMECs were incubated with Dulbecco's modified Eagles medium (DMEM) lacking methionine for 45 min, then labeled with 1.6 mCi/ml of ³⁵S methionine (1,175Ci/mmol) (NEN) in met-free DMEM for 3.5 h at 37°C. All further steps were carried out at 4°C. Cells were harvested and lysed as described before (Hanlon and Sealy, 1999). After clarification, cell extracts were precleared for 90 min with unblocked protein A agarose beads (Gibco, Gaithersburg, MD). Cell extracts were then incubated overnight with BSA-blocked Protein A agarose beads (Calbiochem, San Diego, CA) either alone, or with affinity purified N terminal antibody, or with affinity purified N terminal antibody which had been pre-incubated with excess N terminal peptide to which the antibody was raised. Beads were collected and extensively washed with antibody lysis buffer plus protease/phosphatase inhibitors as given above. The beads were resuspended in 1 × Laemmli SDS sample buffer and boiled 5 min before analyzing samples by SDS 12% polyacrylamide gel electrophoresis. The gel was dried and exposed to film for 5 days.

Primary tissue analysis

Samples of frozen tissue were obtained from the Tissue Procurement Core at Vanderbilt University. The samples were ground at 4°C in 3 ml homogenization buffer (50 mM Tris pH 7.5, 2 mM EDTA, 150 mM NaCl, 2 mM DTT) plus protease/ phosphatase inhibitors (100 μ M Na vanadate, 10 mM benzamidine, 1 mM phenylmethylsulfonyl fluoride, 1 μ g/ml aprotinin, and 1 μ g/ml leupeptin) using a polytron. 1% Triton X-100 was added to the samples which were then left on ice for 5 min before a 10 min, 12,000g centrifugation. Supernatant was used for protein concentration determination or added to an equal volume of 2 × Laemmli sample buffer and boiled for 5 min before being analyzed by SDS 12% polyacrylamide gel electrophoresis. Samples were electrophoresed and transferred to Immobilon-P as described above. Blots were probed as above with either C-terminal antibody or N-terminal antibody.

Cloning of cyclin D1 promoter

Genomic DNA from MDA 231 cells was isolated by standard procedures for use as template. PCR was performed on 1 μ g of the template using the following primers synthesized by Genosys Biotechnologies (5' primer: GGAAGATCTCGCTCACGAATTCAGTCCC and 3' primer: GGATCTAGAGCTCGGCTCTCGCTTCTGC). The 1.192 kb PCR fragment was gel purified and cloned into the PCR Blunt vector from Invitrogen as per manufacturer's instructions. A 1.294 kb fragment containing the cyclin D1 promoter was then cut out of PCR Blunt using *Mlu*I and *Eco*RV, gel purified, and subcloned into the pGL3 Basic luciferase reporter vector from Promega, previously digested with *Mlu*I and *Sma*I.

Cell culture and transfections

HMECs were obtained from Clonetics and maintained in mammary epithelial cell growth medium (MEGM) from that company as per instructions. MCF10A cells were obtained from the ATCC and cultured in a 1:1 mixture of Ham's F12 medium and Dulbecco's modified Eagle's medium with 2.5 mM L-glutamine and supplemented with 20 ng/ml epidermal growth factor, 100 ng/ml cholera toxin, 0.01 mg/ml insulin, 500 ng/ml hydrocortisone, and 5% horse serum (Sigma, St. Louis, MO). NIH 3T3 fibroblasts, from the ATCC, were cultured in Dulbecco's modified Eagle's medium with 10% calf serum (Colorado Serum Company).

HMECs were transfected with 2 μ g of the cyclin D1/luciferase construct (pGL3cycD) and 2 μ g of empty vector (CMV4) or 2 μ g of expression vector for either C/EBP β -1 or C/EBP β -2 using Geneporter liposome (Gene Therapy Systems, San Diego, CA), following manufacturer's instructions. Cells were exposed to the DNA/liposomes for 5 h before the medium was removed and replaced with complete growth medium. Cells were harvested after 36 h. Luciferase assays were carried out using luciferase assay reagent from Promega (Madison, WI), per manufacturer's instructions.

NIH 3T3 cells were transfected with NovaFactor (VennNova, Pompano Beach, FL) as per manufacturer's instructions for 8 h, using the same constructs and amounts as above except when 100 ng of an RSV-LTR/luciferase construct was used as the reporter gene.

Expression vectors

CMV-LAP (C/EBP β -2) was a gift of U. Schibler (University of Geneva, Geneva, Switzerland). CMV4 was developed in the laboratory of David Russell and has been previously described (Andersson et al., 1989). The pcDNA3.1-C/EBP β -1 was constructed by an oligonucleotide mutagenesis approach. First, a pRSETC-NFIL6 construct was generated by digestion of CMV-NFIL6 (a kind gift of S. Akira) with *Sal*I, incubation at 4°C with DNA Polymerase I to generate blunt ends and digestion by *Eco*RI to release a 1,045bp fragment. This fragment was inserted into a pRSETC vector (Invitrogen) that had been previously digested with *Hind*III incubated at 4°C with DNA Polymerase I and digested by *Eco*RI to generate pRSETC-NFIL6. The following oligos (synthesized by Sigma-Genosys, The Woodlands, TX) were used to replace the wild type sequence of pRSETC-NFIL6 (restriction enzyme sites are in lower

case): TOP STRAND: 5' gatctGCAGCTGGTACCATGGGCTACCATGGAACGCCTGGTGGCCTGGGACCAG C ATGTCTCCCCCTGCCGCCGCCGCCGCTG-CCTTTAAATCCGGAGAAGtg3' BOTTOM STRAND: 5' ccaCTTCTCCGGATTAAAGGCAGCGCGCGCGCGCGGAGGAGACATGCTGGGTCCCAGGCCACCA-GGCGTTCCATGGTAGCCCATGGTACCAGCTGCa3'. The oligos were annealed and inserted into a pRSETC-NFIL6 construct that had been previously digested with *Bgl*II and *Msc*I to release a 106 bp fragment. The resulting pRSETC-C/EBP β -1 construct contains a consensus Kozak sequence surrounding the first ATG (underlined) and the second ATG is mutated to a glycine (underlined and italicized). The residues that differ from the wild type NFIL6 sequence are shown in bold. The pRSETC-C/EBP β -1 oligo mutant was then digested with *Hind*III, incubated at 4°C with DNA Polymerase I to generate blunt ends and digested with *Bam*HI to release a 1,082bp fragment. This fragment was inserted into *Bam*HI and *Eco*RV digested pcDNA3.1hisA to generate the pcDNA3.1-C/EBP β -1 construct.

Gel shifts and immobilon analysis

Nuclear and cytoplasmic extracts from HMECs were run on adjacent lanes of a SDS gel and transferred to Immobilon. One lane containing nuclear extracts was cut into 3-mm slices, while parallel lanes of nuclear and cytoplasmic extracts were processed for Western analysis. These 3-mm slices were placed into elution solution (50 mM Tris, pH 7.5, 0.1 mM EDTA, 100 mM NaCl, 100 μ g/ml BSA, 1% Triton X-100, 20% glycerol, 10 mM DTT) at 4°C to recover DNA binding activity. Protein samples from the Immobilon slices representing approximately 97–25 kD were used in electrophoretic mobility shift assays as previously described (Sealy et al., 1997) along with a ³²P labeled 26 bp oligonucleotide representing one of the C/EBP β sites (at -221) in the human beta-casein promoter which has been previously identified by other groups (Doppler et al., 1995; Raught et al., 1995) or the following 27 bp oligonucleotide containing the -559 C/EBP β consensus site (underlined) from the human cyclin D1 promoter: ⁵⁶⁷TAAATTAGTTCTTGCAATTTACACGTG⁻⁵⁴¹.

RESULTS

Normal mammary epithelial cells, but not breast cancer cell lines, express C/EBP β -1.

C/EBP β mRNA gives rise to three different protein products due to alternative use by the ribosome of three translation initiation codons. Two of these proteins are transcriptional activators, differing only by 23 N-terminal amino acids present in human C/EBP β -1 but absent in C/EBP β -2. The third protein product, C/EBP β -3, lacks the N-terminal transactivation domain and is therefore a repressor of transcription (Fig. 1). In order to examine the expression of these different isoforms in human breast cancer cell lines as well as normal mammary cell lines, a series of Western analyses was performed using an antibody specific to the C-terminus of C/EBP β . Also included in this analysis was a single normal cell population, 81N (Band and Sager, 1989). As shown in Figure 2A, all human breast cancer cell lines had significant levels of C/EBP β protein with an estimated MW on our gel system of 45–50 kD. (On the

actual film this band appeared to be a closely spaced doublet of 46 and 49 kD in several lanes). In contrast, the rat or mouse C/EBP β protein (also called LAP) is often observed to be a 35–38 kD doublet. However, the larger size of the human C/EBP β protein (also called NF-IL6) is expected. This is because the NF-IL6 protein is composed of 346 amino acids, 49 amino acids longer than the LAP protein which is only 297 amino acids in length. Some of the breast cancer cell lines analyzed in Figure 2A also contained variable levels of a 21 kD protein likely to be C/EBP β -3. (The rat/mouse C/EBP β -3 protein is also called LIP. Human C/EBP β -3 and LIP have nearly identical MWs of approximately 20–21 kD, because the extra amino acids in the human C/EBP β protein reside primarily in the N-terminal half not included in C/EBP β -3 or LIP). While the normal 81N cells also showed expression of a 45 kD C/EBP β protein, strikingly, only they displayed a more slowly migrating isoform of C/EBP β ranging from 51–59 kD (MW of 55 kD at the band center). Because the antibody used in this analysis was specific to the C-terminus of C/EBP β , and can therefore potentially recognize all three isoforms, one possibility is that the most slowly migrating 55kD band is human C/EBP β -1 and the 45–50 kD proteins are human C/EBP β -2. However, it is also possible that the bands are not different isoforms but variously modified forms of the same isoform. Before embarking on further characterization of the novel 55 kD C/EBP β protein in the normal cells, we wished to determine if this protein was unique to the 81N cells or commonly found in other normal human mammary epithelial cells. Therefore, we purchased from Clonetics normal human mammary epithelial cells (HMECs) that had been placed in culture from an individual undergoing reduction mammoplasty. These cells are primary cells, which have undergone no crisis to survive for prolonged periods in culture. In Figure 2B we analyzed a whole cell extract prepared from the HMECs along with several of the same tumor cell lines used in Figure 2A. Once again all cells expressed 45–50 kD C/EBP β proteins and various levels of p21 or C/EBP β -3. However, only the HMECs contained a more slowly migrating form of C/EBP β at 55 kD. Although the 81N cells were no longer available to us to analyze on the very same immunoblot as the HMECs, based upon its MW the 55kD species in HMECs could likely be the same as the slowly migrating species observed in the 81N cells.

To determine if the 55kD protein observed in normal human mammary epithelial cells is a different isoform of C/EBP β not expressed in the tumor cells, we developed an antibody in our laboratory which is specific to the N terminal amino acids present in human C/EBP β -1 but absent in C/EBP β -2. Because this antibody can recognize only C/EBP β -1, it can be used to definitively distinguish C/EBP β -1 from C/EBP β -2. To characterize the specificity of the antibody, we first expressed bona fide human C/EBP β -1 in a non-mammary, non-human cell line (mouse NIH 3T3 cells) by transient transfection of an expression construct for NF-IL6. The CMV-driven NF-IL6 expression construct was modified to ensure that only C/EBP β -1 would be expressed by mutating the 2nd ATG codon to glycine and creating a perfect Kozak consensus around the first ATG. When affinity-purified N-terminal C/EBP β antibody was used




Fig. 2. Breast cancer cell lines display a different pattern of C/EBP β expression than normal cells. **A:** Whole cell extracts were made from a battery of breast cancer cell lines as well as from a population of normal cells, 81N. Equal amounts of total cell protein were analyzed by SDS-12% polyacrylamide gel electrophoresis. Immunoblotting was

performed with C-terminal C/EBP β antibody (Santa Cruz). **B:** Whole cell extract was prepared from cultured normal human mammary epithelial cells (HMECs) obtained from Clonetics and analyzed in parallel with MDA231, MCF-7, and MDA468 breast cancer cell extracts as in (A).

to immunoblot extracts of transfected or non-transfected NIH 3T3 cells, the antibody reacted with a 58 kD protein present only in the transfected cells (Fig. 3A). To ensure that the 58-kD protein is in fact human C/EBP β -1, we stripped the blot and reprobed with T7 tag monoclonal antibody because the transfected protein carries a T7 tag. The T7 tag antibody recognized the same 58 kD protein as the N-terminal antibody (Fig. 3A). Thus, we conclude that our N-terminal antibody can recognize human C/EBP β -1. Moreover, due to the low transfection efficiency of NIH 3T3 cells, 130 μ g of total cellular protein was loaded onto each lane of the gel in

Figure 3A to enable detection of the transfected protein. While Ponceau S staining confirmed that ample cellular protein was transferred to the filter, the affinity-purified N-terminal antibody did not crossreact appreciably with any other proteins on the Western blot, at least in mouse cells. Interestingly, although the predicted MW of the protein encoded by the human C/EBP β -1 expression vector is 39 kD including the T7 tag (which adds about 3 kD to the MW), the expressed protein actually migrates at 58–62 kD. Thus, we would expect a full length, untagged human C/EBP β -1 protein to migrate on our gel system at approximately 55–59 kD, which is

in good agreement with the 55 kD protein observed in the normal mammary epithelial cells in Figure 2.

To determine if our N-terminal antibody would indeed specifically recognize a 55–59 kD protein in normal mammary epithelial cells, we next performed immunoprecipitation experiments using 35 S-methionine labeled HMECs (Fig. 3B). The antibody precipitated a protein of approximately 59 kD molecular weight (Fig. 3B, lane 4). This interaction was specific, as determined by beads alone (Fig. 3B, lane 2) and peptide blocking controls (Fig. 3B, lane 3). Finally, we performed Western analyses of normal mammary epithelial cells with the affinity-purified N-terminal antibody. For these experiments, HMEC cells were fractionated into cytoplasmic and crude nuclear fractions and duplicate lanes from the same gel were probed with either the N-terminal or C-terminal antibody as indicated in Figure 3C. The N-terminal antibody detected two major bands of 51–58 and 45–48 kD in the crude nuclear fraction prepared from HMECs (Fig. 3C, lane 4). The C-terminal C/EBP β antibody also detected the 51–58 kD band in a parallel sample of HMEC nuclear fraction (Fig. 3C, lane 2). Because this band (denoted simply p55 in the Figure) is recognized by both the C-terminal and N-terminal C/EBP β antibodies and has the same MW as the full length human C/EBP β protein expressed by transient transfection (Fig. 3A), we conclude this protein is C/EBP β -1. The 45–48 kD protein also detected by the N-terminal antibody in the nuclear HMEC fraction could be a cross-reacting protein because it is not recognized by the C-terminal antibody (lane 2). However, the 45–48 kD protein could also represent a slightly proteolyzed form of p55 which has lost the C-terminal epitope and is therefore no longer seen by the C-terminal antibody.

In addition to p55 or C/EBP β -1, the C-terminal antibody also recognized a strong band of 43–45 kD and a more minor doublet of 48 and 50 kD in the cytoplasmic fraction of HMECs (Fig. 3C, lane 1). Due to their nearly full-length size but lack of recognition by the N-terminal antibody (lane 3), these proteins are likely to be C/EBP β -2 and modified forms of C/EBP β -2, respectively. Their cytoplasmic localization will be discussed further in Figure 6. Finally the C-terminal antibody also uniquely detected proteins of 30 and 21 kD which were exclusively nuclear. p30 is likely to represent a proteolytic fragment of a longer C/EBP β isoform and p21 corresponds to the MW for C/EBP β -3 or LIP. Whether p21C/EBP β -3 is generated by alternative translation initiation or proteolysis (artificial or otherwise) in these cells has not been determined.

In Figure 3, we also examined the expression of C/EBP β -1 in several cell types in addition to HMECs. As shown in Figure 3C, lane 6, C/EBP β -1 was not detectable with the N-terminal antibody in a whole cell extract from MCF-7 cells. This is in agreement with Figure 2, where the C-terminal antibody failed to detect a slower migrating 55 kD protein in any of the breast cancer cell lines, including MCF-7. At this time we were also able to obtain mammary ductal epithelial cells (MDEs) which are exfoliated and secreted in human breast milk (Taylor-Papadimitriou et al., 1977; Thompson et al., 1998). Western analysis using the N-terminal antibody showed that MDEs displayed expression of a 55 kD C/EBP β isoform, C/EBP β -1 (Fig. 3C, lane 5). A larger 64 kD

band was also detected by the N-terminal antibody in the MDEs. Both the major 55 kD band as well as the 64 kD MDE-specific band reacted with the C-terminal antibody (data not shown), suggesting that the larger 65 kD band may be a more highly modified form of C/EBP β -1. However, due to a lack of material, we were unable to further characterize this band. Based on the data in Figures 2 and 3, we concluded that C/EBP β -1 is present in normal mammary epithelial cells. C/EBP β -1 was not detectable in the breast cancer cell lines using either the C-terminal (Fig. 2) or the N-terminal antibody (Fig. 3).

C/EBP β -2 expression is absent in normal primary breast tissue

We wanted to investigate whether the difference in expression profiles of C/EBP β between normal and cancer cells in culture were also seen in primary tissues. Frozen samples of tissue taken from reduction mamplasties and from breast tumors were obtained from the Human Tissue Acquisition Core at Vanderbilt University Medical Center. Whole cell extracts were prepared from the tissue samples and analyzed by immunoblotting using the C-terminal C/EBP β antibody. As shown in Figure 4A, a single isoform of C/EBP β at approximately 55 kD was detected with the C-terminal antibody in 12 normal tissue samples obtained from reduction mamplasties (Fig. 4A, left panel). The N-terminal antibody also detected the same size band (Fig. 4A, right panel), confirming that this isoform is C/EBP β -1, since only the full length protein could be recognized by the N-terminal antibody. Interestingly, when ten primary human breast cancer tissue samples were analyzed by immunoblotting, seven of the samples contained an additional C/EBP β protein doublet at 45–48 kD when probed with the C-terminal antibody (Fig. 4B, left panel). The 45–48 kD doublet was particularly abundant in six of the ten samples (T1, T3, and T6–9). On a duplicate blot, the N-terminal antibody failed to detect the 45–48 kD doublet, although a 55 kD species was present at some level in all samples (Fig. 4B, right panel). Because the 45–48 kD doublet is recognized by the C-terminal, but not N-terminal antibody (Fig. 4B, right panel), it is very likely C/EBP β -2. The differential expression of C/EBP β -2 in tumor but not normal tissue is further documented in Figure 5, which is another immunoblot of six of the tumor samples and three of the normal tissue samples directly compared on the same blot. In this darker exposure, minor levels of C/EBP β -2 expression are in fact observed in T4, and also possibly T2 and T5, with the C-terminal antibody in Figure 5A which cannot be detected in Figure 4B. However, absolutely no C/EBP β -2 bands are present in the three normal samples (Fig. 5A, lanes 2–4). In Figure 5B, the blot in 5A was stripped and reprobed with the N-terminal antibody. A 55 kD band was detected by the N-terminal antibody in all samples, while the 45–48 kD protein was not detected. [Note: the gaps in the bands in T5 and T6 are artifactual, as a 55 kD protein was clearly detected in these samples by the N-terminal antibody in Fig. 4B, see left panel].

We conclude that all normal tissue samples express exclusively C/EBP β -1, whereas seven of ten tumor samples had acquired significant C/EBP β -2 expression. The tumor samples also contained C/EBP β -1; however,




Fig. 3. Characterization of the N-terminal human C/EBP β -1 antibody. **A:** NIH 3T3 cells were transfected with 8 μ g of a CMV-driven histagged NFIL6 expression vector modified so that only protein initiating at the first ATG would be produced (+) or control CMV-4 vector (-). Cells were harvested 40 h post-transfection and whole cell extracts prepared and analyzed as in Figure 2. Immunoblotting was performed with the N-terminal C/EBP β or an antibody to the T7 histidine tag (Novagen). **B:** ³⁵S methionine-labeled whole cell extracts from HMEC cells were incubated with agarose beads alone (lane 2), beads plus N-terminal antibody (lane 3), or beads plus N-terminal antibody pre-blocked with 700 ng of N-terminal peptide (lane 4).

Proteins bound to the beads were analyzed by SDS-12% polyacrylamide gel electrophoresis. Autoradiography of the dried gel is shown. **C:** HMECs were fractionated by Triton lysis into a cytoplasmic (lanes 1, 3) and nuclear (lanes 2, 4) fraction. Equal proportions of these fractions were analyzed in duplicate by SDS-12% polyacrylamide gel electrophoresis and immunoblotting was performed with either the C-terminal or N-terminal C/EBP β as indicated. In lanes 5 and 6, whole cell extracts from mammary epithelial cells exfoliated in human breast milk (MDE) or from the MCF-7 human breast cancer cell line were analyzed by SDS-12% polyacrylamide gel electrophoresis and immunoblotting with N-terminal C/EBP β antibody.




Fig. 4. Primary human breast tumors acquire C/EBPβ-2 expression. Whole cell extracts were prepared from normal breast tissue from reductive mammoplasty (A) or breast tumors (B) obtained from the Tissue Procurement Core at Vanderbilt. Equal amounts of total

cell protein were analyzed by SDS-12% polyacrylamide gel electrophoresis. Duplicate gels were subject to immunoblotting with either the C-terminal or N-terminal C/EBPβ as indicated

these samples were comprised of both tumor and normal tissue. Using this analysis, it is impossible to determine in which cells, tumor or normal, the C/EBPβ-1 is expressed. Therefore, it is possible that the C/EBPβ-1 we are detecting is expressed in the surrounding normal tissue. Although the number of tumor samples available to us for analysis was small, the incidence of significant C/EBPβ-2 expression in seven of ten samples compared to zero of 12 normal samples results in a *P*-value of 0.0007 (less than 0.05 in Fisher's exact test) which is statistically significant. Moreover, it is interesting to note that of the ten tumors examined here, seven were high grade, invasive mammary carcinomas, and all seven showed significant C/EBPβ-2 expression. T4, which showed intermediate expression, and T2 were invasive, but of intermediate and low grade, respectively, with T2 being primarily ductal carcinoma in situ. T5 was an encysted male breast tumor with papillary features. However, because the primary tissue samples differ in the percent which is tumor mass, it is difficult to perform quantitative, comparative studies of C/EBPβ-2 expression by immunoblotting.

Breast cancer cell lines display altered subcellular distribution of C/EBPβ-2

Our next step was to investigate the subcellular partitioning of the C/EBPβ isoforms within the normal and cancer cell lines. Immunoblotting was performed on cytoplasmic and nuclear extracts from breast cancer cell lines and normal cell lines. We had previously found that normal HMECs restricted the majority of their C/EBPβ-2 to the cytoplasm (Fig. 3C). This is again the case in Figure 6 (compare lanes 1 and 2) with an isolate of HMECs different from that used in Figure 3. In contrast, cytoplasmic and nuclear extracts prepared in parallel from the breast cancer cell line, MDA 231, and normal, but immortalized MCF 10As, contained much higher levels of C/EBPβ-2 in the nucleus (Fig. 6, compares lanes 2, 4, and 6). The C/EBPβ-2 in the nucleus of the tumor cells (lane 6) also appears to be more modified. Given that multiple kinases are known to phosphorylate C/EBPβ, it is not unlikely that the more slowly migrating bands represent increased phosphorylation of C/EBPβ-2. The N terminal antibody was used to confirm the




Fig. 5. Normal breast tissue from reductive mammoplasty expresses only C/EBP β -1. **A:** Equal amounts of total cell protein from six primary breast tumors (T1-T6) or three normal breast tissue samples from reductive mammoplasty (N1-N3) were analyzed by SDS-12% polyacrylamide gel electrophoresis followed by immunoblotting with

C-terminal C/EBP β antibody. **B:** The immunoblot in (A) was stripped and reprobed with N-terminal C/EBP β antibody. [The blot in (A) was overexposed to show that even with longer exposures, the C-terminal antibody picks up no C/EBP β -2 in the normal samples].

identity of C/EBP β -1 (data not shown). The C/EBP β -1 isoform, present only in the normal cells examined, was strictly nuclear as was the C/EBP β -3 isoform (see Fig. 3C).

C/EBP β -2, but not C/EBP β -1, will activate the cyclin D1 promoter

Given their distinct expression profiles, we next wanted to determine if there are functional differences between C/EBP β -1 and C/EBP β -2. We examined the activity of C/EBP β -1 and C/EBP β -2 at a promoter relevant in breast cancer, cyclin D1. Based on sequence analysis, we identified several putative C/EBP β sites

in the cyclin D1 promoter at -970, -652, -559, -463, and -209. Oligonucleotides representing the five possible sites were radiolabeled and used in EMSAs along with nuclear extracts from the breast cancer cell line MDA 231 (see Fig. 7). One site at -559 bound C/EBP β from the extract, as determined by antibody supershift analysis. From previous work in our laboratory, we suspect that the multiple complexes detected represent homo- and heterodimers of C/EBP β -2 and C/EBP β -3, the two forms of C/EBP β detected in MDA 231 cells.

We used PCR to clone a 1.2 kb fragment of the cyclin D1 promoter from the MDA 231 cell line. This fragment




Fig. 6. Nuclear/cytoplasmic distribution of C/EBP β isoforms in normal and transformed human mammary epithelial cells. Crude nuclear and cytoplasmic extracts were prepared by Triton lysis from HMECs (lanes 1, 2), MCF-10A cells (lanes 3, 4) or MDA231 (lanes 5,

6) breast cancer cells. Equal proportions of nuclear and cytoplasmic extracts were loaded onto a 12% SDS gel transferred to Immobilon-P and probed with C-terminal C/EBP β antibody.

was then subcloned into a luciferase reporter vector, pGL3. Using transient transfections, we determined that all three forms of C/EBP β would regulate the cyclin D1 promoter. In both NIH 3T3 cells and HMECs, C/EBP β -2 activated the cyclin D1 promoter (Fig. 8A). Strikingly, C/EBP β -1, the activator isoform found primarily in the normal non-proliferative breast cells failed to activate, and indeed slightly repressed, the cyclin D1 promoter in both of the cell lines tested. In Figure 8B, the C/EBP β -1 construct was tested using another promoter regulated by C/EBP β , the Rous sarcoma virus (RSV) LTR, to insure that it does encode a functional activator protein. The activity of C/EBP β -3 at the cyclin D1 promoter was also examined. This protein caused substantial repression of the cyclin D1 promoter (data not shown).

C/EBP β -1 will bind DNA

As a first step toward explaining the difference in the ability of the C/EBP β activator isoforms to activate,

we determined whether or not C/EBP β -1 would bind to DNA and the cyclin D1 promoter in particular. Nuclear and cytoplasmic extracts from HMECs were run on adjacent lanes of a SDS gel and transferred to an Immobilon filter. While parallel lanes of nuclear and cytoplasmic extracts were processed for Western analysis, a lane containing nuclear extract was cut into 3-mm slices. These slices were placed into elution solution to recover DNA binding activity. The Immobilon slices representing approximately 97–25 kD were used in gel shifts along with a 32 P labeled oligonucleotide representing the C/EBP β site at –221 in the human beta-casein promoter or the –559 site in the cyclin D1 promoter. Similar results were obtained with either DNA as shown in Figure 9. Binding to both DNA probes was observed from fractions 7 and 8 corresponding to the migration of C/EBP β -1, as confirmed by the Western analysis. Binding was also recovered from fractions 10 and 11, corresponding to the migration of C/EBP β -2. Given the low amount of material recovered from the




Fig. 7. C/EBP β will bind the –559 site in the cyclin D1 promoter. Radiolabeled oligonucleotides representing potential C/EBP β binding sites in the cyclin D1 promoter as depicted in the diagram were incubated with either nuclear extracts from MDA 231 cells or extracts pre-mixed with C-terminal C/EBP β antibody. Reactions were

analyzed by gel electrophoresis and the dried gel was exposed to film. C/EBP β protein-DNA complexes in the autoradiograph are starred. The DNA from the upstream site was older and therefore less radioactive than the other four oligonucleotides.

immobilized slices, it is not possible to carry out competition analyses to demonstrate the binding specificity of fraction #7. However, the binding activity in fraction #7 is diminished and supershifted by C-terminal C/EBP β antibodies, confirming that the DNA binding activity is a 55 kD C/EBP β isoform or C/EBP β -1. We conclude that the failure of C/EBP β -1 to activate the cyclin D1 promoter is not due to a failure to bind DNA. A more complicated scenario such as the inability of C/EBP β -1 to form necessary protein/protein interactions is likely responsible for the inability of this protein to activate this promoter (see Discussion).

DISCUSSION

C/EBP β is a widely expressed transcription factor that can exist as three different isoforms, the full length protein, C/EBP β -1, a 23 amino acid N-terminally

truncated protein, C/EBP β -2, and a protein with a large N-terminal truncation, C/EBP β -3. Using a new antibody specific for the N-terminal amino acids unique to human C/EBP β -1, we uncovered substantial differences in the expression of C/EBP β -1 and -2 in normal and transformed mammary epithelial cells. C/EBP β -2 was not detected in normal, mostly non-dividing tissue from reduction mamoplasties, which expressed only C/EBP β -1. Abundant C/EBP β -1 expression was also detected in secretory mammary epithelial cells exfoliated in human breast milk, where an additional, potentially more highly modified form of C/EBP β -1 was also observed. In contrast, a majority of primary human breast tumors examined had acquired significant levels of C/EBP β -2 expression. C/EBP β -2 was also the principal isoform expressed in all cultured breast cancer cell lines we examined; none of these tumor cell




Fig. 8. C/EBP β -2, but not C/EBP β -1, will activate the cyclin D1 promoter. **A:** HMECs were transfected for 5 h with 2 μ g of the cyclin D1/luciferase construct (pGL3cycD) and 2 μ g of empty vector (CMV4) or 2 μ g of expression vector for either C/EBP β -1 or C/EBP β -2 using Geneporter liposomes. NIH 3T3 cells were transfected for 8 h with

the same DNAs using Novafector liposomes. Data are the average of three separate experiments with duplicate samples. **B:** NIH 3T3 cells were transfected as in (A) except that calcium phosphate precipitation was used and samples contained 100 ng of an RSV LTR luciferase reporter gene.

lines expressed C/EBP β -1. Interestingly, we obtained similar results when we examined other tissues, namely prostate and colon. That is to say, C/EBP β -2 is the major isoform in prostate and colon carcinoma cell lines, whereas samples of normal, primary prostate, and colon tissue express C/EBP β -1 exclusively.

It is important to note that the analysis of primary breast tumors and normal breast tissue was not meant to be a clinical study but to demonstrate that C/EBP β -2 expression is not an idiosyncrasy of breast cancer cell lines. Because C/EBP β -1 was also detected by immunoblotting in the primary breast tumor samples, lack of C/EBP β -1 in the breast tumor cell lines could reflect an adaptation to prolonged growth in culture. However, because the primary breast tumor samples were heterogeneous in nature consisting of both normal and tumor tissue, we cannot exclude the possibility that the C/EBP β -1 detected in the immunoblots actually arises from the surrounding normal and not tumor tissue. In situ immunohistochemical analyses with the N-terminal antibody will be necessary to resolve this issue, studies we are currently pursuing.

Although C/EBP β -1 and -2 are both transactivators, their distinct expression profiles suggested that functional differences might exist between the two isoforms. Because significant C/EBP β -2 expression had been acquired by seven of ten human breast tumors and this was the only C/EBP β activator isoform expressed in the cultured breast tumor cell lines, we tested whether C/EBP β -2 could transactivate the promoter of the cyclin D1 gene in transient cotransfection experiments. Indeed, transactivation was observed by C/EBP β -2 but not C/EBP β -1. While this work was in progress Kowenz-Leutz and Leutz (1999) reported on functional differences between rat C/EBP β -1 and -2 (called LAP* and LAP, respectively in their work), demonstrating that only C/EBP β -1, but not C/EBP β -2, can cooperate with Myb to activate the differentiation specific *mim-1* gene in chromatin. This specificity is likely due to the interaction of the N-terminal amino acids of LAP*, or C/EBP β -1, with the SWI/SNF chromatin remodeling complex. Kowenz-Leutz and Leutz did not observe functional differences between LAP* and LAP in transient transfection assays unless the cell line was




Fig. 9. C/EBP β -1 will bind DNA. Western blot of cytoplasmic and nuclear extracts from HMECs probed with C-terminal C/EBP β antibody is shown in the top panel. A parallel lane of the filter containing nuclear extract was cut into 3-mm slices and proteins eluted from slices representing approximately 97–25 kD were used in EMSAs along with 32 P labeled DNAs representing the C/EBP β sites in the beta-casein promoter (middle panel) or the –559 site in the cyclin

D1 promoter (lower panel); along with DNA binding assays were run on adjacent lanes of an SDS gel and transferred to Immobilon. The DNA binding assay was repeated with fraction #7 (corresponding to the apparent MW of C/EBP β -1) and beta-casein DNA except that fraction #7 was preincubated with C-terminal C/EBP β antibody (lane 2) or BSA (lane 1) prior to the addition of radiolabeled DNA.

deficient in SWI/SNF functions. Our results extend their observations by showing that functional differences between C/EBP β -1 and -2 can also be observed in transient transfection assays with certain promoters, such as cyclin D1. The transactivation domain of C/EBP β common to both C/EBP β -1 and -2 in the N-terminal half of the protein is known to interact with other factors involved in transcriptional activation such as TBP, TFIIB, and the coactivator and histone acetylase CBP/p300 (Nerlov and Ziff, 1995; Mink et al., 1997). Although we do not know which factors C/EBP β -2 is interacting with to transactivate the cyclin D1 promoter, it is possible that the additional amino acids of C/EBP β -1 block this interaction, either sterically, or by interacting with another distinct set of factors such as the SWI-SNF chromatin remodeling complex.

The ability of C/EBP β -1 to interact with the SWI-SNF chromatin remodeling complex supports our proposal that C/EBP β -1 regulates differentiation-specific genes and C/EBP β -2 targets growth-promoting genes. While there may be some genes that are transactivated equally well by both C/EBP β -1 and -2, the commitment of cells to a differentiation pathway requires the activation of transcriptionally-silent genes in chromatin and thus a transcription factor capable of overcoming the repressive effects of chromatin. Alveolar development and differentiation of mammary epithelial cells is severely impaired in pregnant C/EBP β -null mice (Robinson et al., 1998; Seagroves et al., 1998). The differentiation program leading to a functional gland is not executed, as the expression of milk proteins such as WAP, WNM1, and β -casein is undetectable in C/EBP β -null mice at term (Robinson et al., 1998; Seagroves et al., 1998). The sole expression of C/EBP β -1 in normal, mostly non-dividing mammary tissue, as well as the presence of a more slowly migrating, possibly more modified form of C/EBP β -1 in secretory mammary epithelial cells that have been actively expressing milk proteins strongly suggests that C/EBP β -1 is involved in transactivating the promoters of the milk protein genes either directly (such as β -casein) or indirectly. During the differentiation of other cell types, C/EBP β acts in a combinatorial fashion with other transcription factors. For example, C/EBP β plus Myb leads to differentiation along the myeloid lineage (Burk et al., 1993; Ness et al., 1993), whereas C/EBP β collaborates with the transcription factor PPAR γ to specify adipogenic differentiation (Wu et al., 1995). Whether C/EBP β -1 collaborates with another transcription factor(s) in the early stages of mammary epithelial differentiation remains to be determined.

Evidence has recently been accumulating that C/EBP β plays an important role in cellular proliferation during liver regeneration. Following partial hepatectomy, mice lacking the C/EBP β gene display impaired liver regeneration (Greenbaum et al., 1998) and C/EBP β ^{-/-} mouse hepatocytes are refractory to the growth-promoting effects of TGF α (Buck et al., 1999). The latter defect can be rescued by re-expression of C/EBP β in the C/EBP β ^{-/-} cells. We have shown that C/EBP β is involved in activating the serum response element in the promoter of an early response gene, *c fos*, by forming a complex with serum response factor (Hanlon and Sealy, 1999). C/EBP β

is required for the proliferation of mammary epithelial cells (Robinson et al., 1998; Seagroves et al., 1998), and our data indicate that C/EBP β -2 is likely to be the responsible isoform. It is the only activator isoform of C/EBP β expressed in the breast cancer cell lines we examined, it is capable of activating the cyclin D1 promoter, and C/EBP β -2 expression is acquired by a majority of primary breast tumors we examined.

Although tissue from reduction mammoplasties lacks C/EBP β -2 expression, mammary epithelial cells from reduction mammoplasties (HMECs) placed in a rich growth medium in culture acquire C/EBP β -2 expression. However, C/EBP β -2 expressed in normal mammary epithelial cells (HMECs) is primarily cytoplasmic. Breast cancer cells display a much higher proportion of C/EBP β -2 in the nucleus. Since little is known about the mechanism(s) regulating cytoplasmic to nuclear transport of C/EBP β -2, it is not clear how growth-promoting signals influence the proportion of C/EBP β -2 in the nucleus. Any mechanism must also explain why C/EBP β -2 can be sequestered in the cytoplasm whereas C/EBP β -1, with its 21–23 amino acid N-terminal extension, appears to be constitutively nuclear.

Also of note is the fact that nuclear C/EBP β is more highly modified in the breast cancer cells, compared with the nuclear C/EBP β of the primary HMECs. C/EBP β is the target of several mitogenic signaling pathways, including some of interest in the context of breast cancer. Activated Ras causes phosphorylation of C/EBP β at Thr 235 via the MAP kinase pathway in vivo and in vitro (Nakajima et al., 1993; Hanlon and Sealy, 1999). At least one consequence of this phosphorylation is potentiation of the transactivation by C/EBP β of the *c fos* serum response element (Hanlon and Sealy, 1999). Serum response factor (SRF) recruits C/EBP β to the SRE; however, C/EBP β and SRF interact only upon Ras-dependent phosphorylation of C/EBP β by ERK2 and p90Rsk2. Work in our laboratory has indicated that C/EBP β is a target of the PI3Kinase pathway as well (Hanlon et al, manuscript submitted). Both ras and PI3Kinase are among the targets of *erbB-2* signaling (reviewed in Reese and Slamon, 1997); studies evaluating the effects of *erbB-2* upon C/EBP β , particularly C/EBP β -2, will prove interesting.

In this work, we also observed differences in the expression of C/EBP β -3 among the normal mammary epithelial and breast tumor cells that we studied. Zahnnow et al. (1997) detected C/EBP β -3 (also known as LIP) overexpression in a subset of infiltrating ductal carcinoma specimens. They propose that C/EBP β -3 expression is oncogenic (Zahnnow et al., 1997). In this study, seven of the ten tumor specimens examined were considered high grade infiltrating mammary carcinomas; however, none expressed any appreciable level of C/EBP β -3. C/EBP β -3 was detected in some of the breast cancer cell lines (Fig. 2) although generally at low levels with the exception of the MDA 468 cells. However, even higher levels of C/EBP β -3 than present in the MDA 468 cells were detected in HMECs growing in culture (see Fig. 3) and these cells are neither transformed nor immortalized. Thus, there does not appear to be a strong correlation between high level of C/EBP β -3 expression and transformation of mammary epithelial cells. Unfor-

tunately, analysis of C/EBP β -3 levels in cells is complicated by the propensity of the longer forms of C/EBP β to undergo proteolytic degradation during in vitro manipulations of cells or tissues (Baer and Johnson, 2000). Extreme care to prevent adventitious proteolysis is required before meaningful conclusions about C/EBP β -3 levels in cells can be obtained.

The N-terminal antibody we describe here has been a valuable tool to document differences in expression of C/EBP β -1 and -2 in normal vs. transformed mammary epithelial cells. That these differences have functional significance is supported by our preliminary experiments with the cyclin D1 promoter. Whether C/EBP β -2 promotes growth of mammary epithelial cells by upregulating cyclin D1 expression will require additional studies in which the consequences of increased C/EBP β -2 expression in the nucleus of normal mammary epithelial cells is addressed. This may require deciphering the mechanisms by which normal mammary epithelial cells sequester C/EBP β -2 in the cytoplasm, a feature apparently lost in tumor cells. Although we selected the cyclin D1 gene because it has been strongly implicated in the pathogenesis of breast cancer, there are likely to be many other genes differentially regulated by C/EBP β -1 vs. C/EBP β -2 in mammary epithelial cells. The emerging microarray technology should be extremely useful for capturing on a genomic scale the functional differences in gene regulation by C/EBP β -1 and -2 in mammary epithelial cells.

ACKNOWLEDGMENTS

The authors would like to acknowledge John Van Doorninck for excellent technical assistance as well as Carlos Arteaga for both cell lines and advice. Katie Tipton is thanked for technical assistance and Matthew Chalkley for giving up his lunch. The Human Tissue Acquisition core at VUMC is thanked for tissue samples. E.E. and M.H. were supported in part by pre-doctoral training fellowships from the NIH (2T32DK07563-13) and (2T32GM08554-06). E.E. was also supported by a dissertation research award from the Susan G. Komen Breast Cancer Research Foundation.

LITERATURE CITED

- Andersson S, Davis DL, Dahlback H, Jornvall H, Russell DW. 1989. Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. *J Biol Chem* 264:8222-8229.
- Baer M, Johnson P. 2000. Generation of truncated C/EBP β isoforms by in vitro proteolysis. *J. Biol. Chem* 275:26582-26590.
- Band V, Sager R. 1989. Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. *Proc Natl Acad Sci USA* 86:1249-1253.
- Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. 1994. Cyclin D1 protein expression and function in human breast cancer. *Int J Cancer* 57:353-361.
- Buck M, Poli V, van der Geer P, Chojkier M, Hunter T. 1999. Phosphorylation of rat serine 105 or mouse threonine 217 in C/EBP β is required for hepatocyte proliferation induced by TGF α . *Mol Cell* 4:1087-1092.
- Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson R I, deFazio A, Watts CK, Musgrove EA, Sutherland RL. 1993. Expression and amplification of cyclin genes in human breast cancer. *Oncogene* 8:2127-2133.
- Burk O, Mink S, Ringwald M, Klempnauer KH. 1993. Synergistic activation of the chicken mim-1 gene by v-myb and C/EBP transcription factors. *Embo J* 12:2027-2038.
- Descombes P, Schibler U. 1991. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. *Cell* 67:569-579.
- Doppler W, Welte T, Philipp S. 1995. CCAAT/enhancer-binding protein isoforms beta and delta are expressed in mammary epithelial cells and bind to multiple sites in the beta-casein gene promoter. *J Biol Chem* 270:17962-17969.
- Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C. 1995. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. *Genes Dev* 9:2364-2372.
- Greenbaum LE, Li W, Cressman DE, Peng Y, Ciliberto G, Poli V, Taub R. 1998. CCAAT enhancer-binding protein beta is required for normal hepatocyte proliferation in mice after partial hepatectomy. *J Clin Invest* 102:996-1007.
- Hanlon M, Sealy L. 1999. Ras regulates the association of serum response factor and CCAAT/enhancer-binding protein beta. *J Biol Chem* 274:14224-14228.
- Kowenz-Leutz E, Leutz A. 1999. A C/EBP beta isoform recruits the SWI/SNF complex to activate myeloid genes [In Process Citation]. *Mol Cell* 4:735-743.
- Lekstrom-Himes J, Xanthopoulos KG. 1998. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. *J Biol Chem* 273:28545-28548.
- Mink S, Haenig B, Klempnauer KH. 1997. Interaction and functional collaboration of p300 and C/EBP β . *Mol Cell Biol* 17:6609-6617.
- Nakajima T, Kinoshita S, Sasagawa T, Sasaki K, Naruto M, Kishimoto T, Akira S. 1993. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. *Proc Natl Acad Sci USA* 90(6):2207-2211.
- Nerlov C, Ziff EB. 1995. CCAAT/enhancer binding protein-alpha amino acid motifs with dual TBP and TFIIB binding ability cooperate to activate transcription in both yeast and mammalian cells. *Embo J* 14:4318-4328.
- Ness SA, Kowenz-Leutz E, Casini T, Graf T, Leutz A. 1993. Myb and NF-M: combinatorial activators of myeloid genes in heterologous cell types. *Genes Dev* 7:749-759.
- Raught B, Liao WS, Rosen JM. 1995. Developmentally and hormonally regulated CCAAT/enhancer-binding protein isoforms influence beta-casein gene expression. *Mol Endocrinol* 9:1223-12232.
- Reese DM, Slamon DJ. 1997. HER-2/neu signal transduction in human breast cancer and ovarian cancer. *Stem Cells* 15:1-8.
- Robinson GW, Johnson PF, Hennighausen L, Sterneck E. 1998. The C/EBP β transcription factor regulates epithelial cell proliferation and differentiation in the mammary gland. *Genes Dev* 12:1907-1916.
- Seagroves TN, Krnacik S, Raught B, Gay J, Burgess-Beusse B, Darlington GJ, Rosen JM. 1998. C/EBP β , but not C/EBP α , is essential for ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland. *Genes Dev* 12:1917-1928.
- Sealy L, Malone D, Pawlak M. 1997. Regulation of the cfos serum response element by C/EBP β . *Mol Cell Biol* 17:1744-1755.
- Sherr CJ. 1996. Cancer cell cycles. *Science* 274:1672-1677.
- Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam S.Z, Bronson RT, Elledge SJ, Weinberg RA. 1995. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. *Cell* 82:632-630.
- Taylor-Papadimitriou J, Shearer M, Tilly R. 1977. Some properties of cells cultured from early-lactation human milk. *J Natl Cancer Inst* 58:1563-1571.
- Thompson PA, Kadlubar FF, Vena SM, Hill HL, McClure GH, McDaniel LP, Ambrosone CB. 1998. Exfoliated ductal epithelial cells in human breast milk: a source of target tissue DNA for molecular epidemiologic studies of breast cancer. *Cancer Epidemiol Biomarkers Prev* 7:37-42.
- Timchenko NA, Welm AL, Lu X, Timchenko LT. 1999. CUG repeat binding protein (CUGBP1) interacts with the 5' region of C/EBP β mRNA and regulates translation of C/EBP β isoforms. *Nucleic Acids Res* 27:4517-4525.
- Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. 1994. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. *Nature* 369:669-671.

- Wu Z, Xie Y, Bucher NL, Farmer SR. 1995. Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis. *Genes Dev* 9:2350-2363.
- Zahnow CA, Younes P, Laucirica R, Rosen JM. 1997. Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer. *J Natl Cancer Inst* 89:1887-1891.